Lilly Is Growing Its Next Crop Of Blockbusters

Eli Lilly and Company is counting on five key near-term approvals for organic growth, and offered investors a deep dive into those programs during a 15 December financial guidance and R&D overview, as well as highlighting how its focus on certain core disease areas is resulting in a robust mid- and early-stage pipeline.

Guggenheim Securities analyst Seamus Fernandez deemed it “a surprisingly broad and robust mid-stage pipeline” in a 16 December note, while Mizuho Securities analyst Vamil Divan highlighted “the progress Lilly continues to make with its pipeline” in a same-day analysis